Aducanumab tops 2021’s biggest potential launches
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
The biotech resurrection continues
Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.
Corporate and regulatory developments over the Christmas period
Myovant and Pfizer showed that deal-making was not taking a Christmas break, but for Celgene CVR holders the dream is almost over. And vaccine approvals gained pace.
Europe backs Pfizer/Biontech Covid-19 vaccine's broad applicability
An extraordinary meeting of the EU CHMP recommends conditional approval of Pfizer/Biontech’s Covid-19 vaccine.
A new setting for antigen testing
It is vital that the first authorised at-home, non-prescription Covid-19 antigen test be used in the right way.
Covid-19 vaccine developers remind the world that setbacks happen
As Biontech and Pfizer’s Covid-19 vaccine gets a positive US vote, delays for Sanofi, Glaxo and CSL show that top-speed drug development is the exception.
Prescription apps take off during lockdown
Digital therapeutics are going from strength to strength during the pandemic.
UK asserts its independence with first Covid-19 vaccine nod
The UK’s swift authorisation of Biontech and Pfizer’s Covid-19 shot has attracted both praise and concern.
FDA sends Reata back to the drawing board
The need for another pivotal trial of omaveloxolone in Friedreich's ataxia looks increasingly likely.
